Download PDF

1. Company Snapshot

1.a. Company Description

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally.It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.


Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates.This segment also offers microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications.The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production, and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; and choline chloride, a nutrient for monogastric animal health.


The Specialty Products segment offers ethylene oxide primarily for use in the health care industry; and single use canisters with ethylene oxide for sterilizing re-usable devices.This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops.The company sells its products through sales force, independent distributors, and sales agents.


Balchem Corporation was incorporated in 1967 and is headquartered in New Hampton, New York.

Show Full description

1.b. Last Insights on BCPC

Balchem Corporation's recent performance was driven by its strong quarterly results, despite missing earnings estimates. The company reported a 25% increase in revenue year-over-year, driven by its health and nutrition segment. Additionally, Balchem's Board of Directors declared a dividend of $0.87 per share, indicating a commitment to returning value to shareholders. Furthermore, the company's announcement of a quarterly conference call for its fourth-quarter and full-year 2024 results suggests a transparent approach to sharing its financial performance with investors.

1.c. Company Highlights

2. Balchem's Strong FY2025 Results: Growth Across Segments

Balchem Corporation reported record fourth quarter consolidated sales of $264 million, a 9.8% increase from the prior year, and record full-year sales of $1.037 billion, an 8.8% growth. The company's adjusted EBITDA for the full year was $275 million, up 9.8%, and adjusted net earnings per share for the fourth quarter was $1.31, beating estimates of $1.29. Gross margin dollars for the fourth quarter were $94 million, up 8.8%, but gross margin percentage was 35.6%, down 40 basis points due to higher manufacturing input costs.

Publication Date: Feb -22

📋 Highlights
  • Record Full-Year Sales:: Achieved $1,037M in 2025, a 8.8% increase from the prior year, surpassing the $1B threshold for the first time.
  • Adjusted EBITDA Growth:: Generated $275M in adjusted EBITDA, reflecting a 9.8% year-over-year increase driven by operational efficiency and pricing.
  • Free Cash Flow Strength:: Delivered $174M in free cash flow while investing $43M in capital projects to support long-term growth.
  • Share Repurchases and Dividend Rise:: Repurchased 685K shares at $158 average and boosted dividend to $0.96/share (10% increase YoY).
  • Fourth-Quarter Sales Surge:: Q4 sales hit $264M, up 9.8% YoY, with adjusted net earnings of $42M, a 14.8% increase over the prior year.

Segment Performance

The Human Nutrition and Health segment drove growth with sales of $166 million, a 12.7% increase, led by higher sales in Nutrients and Food Ingredients and Solutions businesses. The Animal Nutrition and Health segment saw sales of $61 million, up 4.9%, while the Specialty Products segment delivered sales of $35 million, a 6% increase, driven by the Performance Gases business.

Valuation and Outlook

With a P/E Ratio of 35.75 and an EV/EBITDA of 21.68, the market is pricing in a certain level of growth. Analysts estimate next year's revenue growth at 4.3%. Given Balchem's strong competitive positions and differentiated product portfolio, the company is well-positioned to deliver continued top and bottom-line growth. The company's guidance on the effective tax rate of 23% for modeling purposes and its plans to continue investing in marketing and partnerships are positive indicators.

Growth Initiatives and International Expansion

Balchem is focused on expanding its presence in international markets, with half of its recent growth coming from outside the US. The company is investing in marketing campaigns for its MSM product and exploring partnerships with professional sports leagues. As Ted Harris mentioned, "We are excited about 2026, and I believe the company is well-positioned to deliver continued top and bottom-line growth on a full-year basis while further advancing our important growth initiatives."

Tariff Impact and Risk Management

The company is relatively well-shielded from the potential impact of tariffs, with a manageable effect of around $20 million. Balchem's regional manufacturing and strong market positions have allowed it to raise prices to offset tariffs. The company's diversified portfolio and geographic expansion plans help mitigate potential risks.

3. NewsRoom

Card image cap

Balchem: An Attractive Valuation Makes This Stock A Buy

Mar -27

Source: seekingalpha.com

Card image cap

Balchem Launches Metalosate® T.E.A.M.™ Plant Tissue Analysis Digital Platform to Deliver Research-Driven Nutrient Recommendations for Specialty Crops

Mar -09

Source: globenewswire.com

Card image cap

Balchem Stock Lands New $18 Million Investor as Firm Delivers Record $1 Billion in Sales

Mar -04

Source: fool.com

Card image cap

Balchem Corporation to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026

Feb -25

Source: globenewswire.com

Card image cap

Balchem Corporation to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026

Feb -24

Source: globenewswire.com

Card image cap

Balchem Corporation (BCPC) Q4 2025 Earnings Call Transcript

Feb -20

Source: seekingalpha.com

Card image cap

First Look: Amazon tops Walmart; WBD--Netflix saga; oil up

Feb -20

Source: gurufocus.com

Card image cap

Balchem Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

Feb -20

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.00%)

6. Segments

Human Nutrition and Health

Expected Growth: 4%

Balchem's Human Nutrition and Health segment growth is driven by increasing demand for omega-3 fatty acids, vitamins, and minerals in food and pharmaceutical applications. Rising health awareness, growing popularity of functional foods, and expanding use of nutraceuticals in animal feed also contribute to this growth.

Animal Nutrition and Health

Expected Growth: 3%

Balchem's Animal Nutrition and Health segment growth is driven by increasing demand for sustainable and healthy animal feed, rising adoption of precision livestock farming, and growing awareness of animal welfare. Additionally, the company's strategic acquisitions and investments in research and development have expanded its product offerings and enhanced its market position.

Specialty Products

Expected Growth: 6%

Balchem Corporation's Specialty Products segment growth is driven by increasing demand for value-added ingredients in food and beverage, pet food, and pharmaceutical industries. Rising health consciousness and pet humanization trends fuel growth. Additionally, strategic acquisitions and investments in R&D enhance product offerings and expand market reach, contributing to the 6% growth rate.

Other and Unallocated

Expected Growth: 2%

Balchem Corporation's Other and Unallocated segment growth is driven by increasing demand for specialty products, expansion into new markets, and strategic acquisitions. Additionally, the company's focus on innovation and R&D investments in emerging technologies, such as plant-based and clean label products, contributes to its growth momentum.

7. Detailed Products

Reashure

A line of choline-based ingredients for human nutrition and animal health

Nitroshure

A line of nitrate-based ingredients for animal nutrition

AminoShure

A line of amino acid-based ingredients for animal nutrition

Choline Chloride

A feed-grade choline chloride for animal nutrition

Selenium Supplements

A line of selenium-based ingredients for animal nutrition

Ethoxquin

A feed preservative for animal nutrition

Custom Premixes

Customized blends of vitamins, minerals, and other nutrients for animal nutrition

8. Balchem Corporation's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Balchem Corporation is medium due to the availability of alternative products in the market, but the company's strong brand presence and customer loyalty mitigate this threat.

Bargaining Power Of Customers

The bargaining power of customers for Balchem Corporation is low due to the company's diversified customer base and lack of concentration of customers, which reduces their bargaining power.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Balchem Corporation is medium due to the presence of multiple suppliers, but the company's large scale of operations and long-term contracts with suppliers reduce their bargaining power.

Threat Of New Entrants

The threat of new entrants for Balchem Corporation is low due to the high barriers to entry in the industry, including significant capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry for Balchem Corporation is high due to the presence of several established players in the industry, leading to intense competition and pricing pressure.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 22.94%
Debt Cost 7.52%
Equity Weight 77.06%
Equity Cost 7.52%
WACC 7.52%
Leverage 29.77%

11. Quality Control: Balchem Corporation passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Balchem

A-Score: 4.9/10

Value: 1.9

Growth: 5.4

Quality: 7.5

Yield: 1.0

Momentum: 4.0

Volatility: 9.3

1-Year Total Return ->

View Full Report
Stock-Card
Element Solutions

A-Score: 4.8/10

Value: 3.6

Growth: 6.2

Quality: 6.0

Yield: 2.0

Momentum: 4.5

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
H.B. Fuller

A-Score: 4.6/10

Value: 4.9

Growth: 4.9

Quality: 4.4

Yield: 3.0

Momentum: 2.5

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
Minerals Technologies

A-Score: 4.2/10

Value: 6.6

Growth: 4.3

Quality: 3.4

Yield: 1.0

Momentum: 2.5

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Olin

A-Score: 4.1/10

Value: 7.1

Growth: 4.3

Quality: 2.4

Yield: 6.0

Momentum: 1.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Westlake

A-Score: 4.1/10

Value: 7.7

Growth: 4.0

Quality: 3.3

Yield: 4.0

Momentum: 0.5

Volatility: 5.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

172.41$

Current Price

172.41$

Potential

-0.00%

Expected Cash-Flows